PMA supplement
P250024 S006: Trilogy Transcatheter Heart Valve System
FDA PMA supplement · 30-Day Notice · JenaValve Technology, Inc.
Key facts
| Original PMA | P250024 |
|---|---|
| Supplement number | S006 |
| Supplement type | 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | Trilogy Transcatheter Heart Valve System |
| Generic name | Aortic valve, prosthesis, percutaneously delivered |
| Applicant | JenaValve Technology, Inc. |
| Product code | NPT |
| Received date | Sep 28, 2026 |
| Decision date | Oct 7, 2026 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: